A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma

Gynecologic Oncology

Volumn 104, Issue 2, 2007, Pages 422-427

  Elkas, John C ^a   Winter III, William E ^b   Chernofsky, Mildred R ^a   Sunde, Jan ^a   Bidus, Michael A ^a   Bernstein, Sarah ^a   Rose, G Scott ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

Ovarian cancer; Oxaliplatin; Phase I; Topotecan

Indexed keywords

CA 125 ANTIGEN; DEXAMETHASONE; DNA TOPOISOMERASE; ERYTHROPOIETIN; GRANISETRON; OXALIPLATIN; PLATINUM DERIVATIVE; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; IN VITRO STUDY; KIDNEY FUNCTION; LIVER FUNCTION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CARCINOMA; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; TOPOTECAN;

EID: 33846342196     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.08.011     Document Type: Article

References (29)

1. Hainsworth J.D., Grosh W.W., Burnett L.S., Jones III H.W., Wolff S.N., and Greco F.A. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann. Intern. Med. 108 (1988) 165-170
2. Neijt J.P., ten Bokkel Huinink W.W., van der Burg M.E., van Oosterom A.T., Willemse P.H., Heintz A.P., et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J. Clin. Oncol. 5 (1987) 1157-1168
3. Omura G.A., Bundy B.N., Berek J.S., Curry S., Delgado G., and Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma. A Gynecologic Oncology Group study. J. Clin. Oncol. 7 (1989) 457-465
4. Louie K.G., Ozols R.F., Myers C.E., Ostchega Y., Jenkins J., Howser D., et al. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J. Clin. Oncol. 4 (1986) 1579-1585
5. McGuire W.P., and Ozols R.F. Chemotherapy of advanced ovarian cancer. Semin. Oncol. 25 (1998) 340-348
6. O'Reilly S., Rowinsky E.K., Slichenmyer W., Donehower R.C., Forastiere A.A., Ettinger D.S., et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J. Clin. Oncol. 14 (1996) 3062-3073
7. Rowinsky E.K., Grochow L.B., Hendricks C.B., Ettinger D.S., Forastiere A.A., Hurowitz L.A., et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol. 10 (1992) 647-656
8. Houghton P.J., Cheschire P.J., Hallman II J.D., Lutz L., Friedman H.S., Danks M.K., et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol. 36 (1995) 393-403
9. Bookman M.A., Malmstrom H., Bolis G., Gordon A., Lissoni A., Krebs J.B., and Fields S.Z. Topotecan for the treatment of advanced epithelial ovarian cancer: an open label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol. 16 (1998) 3345-3352
10. McGuire W.P., Blessing J.A., Bookman M.A., Lentz S.S., and Dunton C.J. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 18 (2000) 1062-1067
11. Homesley H., Hall D., Martin D.A., Lewandowski G.S., Vaccarello L., Nahhas W.A., et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol. Oncol. 83 (2001) 394-399
12. Dieras V., Bougnoux P., Petit T., Chollet P., Beuzeboc P., Borel C., et al. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin ± taxane-pretreated ovarian cancer patients. Ann. Oncol. 13 (2002) 258-266
13. Fracasso P.M., Blessing J.A., Morgan M.A., Sood A.K., and Hoffman J.S. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. J. Clin. Oncol. 21 (2003) 2856-2859
14. Sundar S., Symonds R.P., Decatris M.P., Kumar D.M., Osman A., Vasanthan S., et al. Phase II trial of oxaliplatin and 5-fluorouracil/leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. Gynecol. Oncol. 94 (2004) 502-508
15. Tortora G., Ciardiello F., Damiano V., De Laurentiis M., Matano E., Pepe S., et al. Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer. Ann. Oncol. 13 (2002) 392-398
16. Chollet P., Bensmaine M.A., Brienza S., Deloche C., Cure H., Caillet H., et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann. Oncol. 7 (1996) 1065-1070
17. Piccart M.J., Green J.A., Lacave A.J., Reed N., Vergote I., Benedetti-Panici P., et al. Oxaliplatin or paclitaxel in patients with platinum pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J. Clin. Oncol. 18 (2000) 1193-1202
18. Dieras V., Bougnoux P., Petit T., Chollet P., Borel C., Husseini F., et al. Oxaliplatin (L-OHP) phase II study in platinum (PT) pretreated advanced ovarian cancer (AOC): preliminary results [abstract]. Proc. Am. Soc. Clin. Oncol. 17 (1998) 364a [Abstract 1405]
19. Pendyala L., and Creaven P.J. In vitro cytotoxicity, protein-binding red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 53 (1993) 5970-5976
20. Goldwasser F., Bozec L., Zeghari-Squalli N., and Misset J.L. Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line. Anticancer Drugs 10 (1999) 195-201
21. Alexandre J., Tigaud J.M., Gross-Goupil M., Gornet J.M., Romain D., Azoulay D., et al. Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. Am. J. Clin. Oncol. 25 (2002) 198-203
22. Gross-Goupil M., Lokiec F., Lopez G., Tigaud J.M., Hasbini A., Romain D., et al. Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients. Eur. J. Cancer 38 (2002) 1888-1898
23. Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
24. Bhoola S.M., Coleman R.L., Herzog T., Morris R., Bryant C., Estes J.M., and Alvarez R.D. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol. Oncol. 95 (2004) 564-5649
25. Seliger G., Mueller L.P., Buechele T., Kellner O., Grothey A., Strauss H.G., et al. Salvage chemotherapy with docetaxel, oxaliplatin and gemcitabine in platinum-pretreated advanced epithelial ovarian cancer: preliminary results of a phase II study. [Abstract]. Proc. Am. Soc. Clin. Oncol. 21 (2002) 217a [Abstract 864]
26. Hochster H., Liebes L., Speyer J., Sorich J., Taubes B., Oratz R., et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J. Clin. Oncol. 12 (1994) 553-559
27. Hochster H., Wadler S., Runowicz C., Liebes L., Cohen H., Wallach R., et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J. Clin. Oncol. 17 (1999) 2553-2561
28. Goldwater F., Buthaud X., Gross M., Bleuzen P., Cvitkovic E., Voinea A., et al. Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients. Anticancer Drugs 10 (1999) 263-265
29. Lu J., Hochster H., Sorich J., Francois A., Escalon P., Ivy M., et al. Phase I study of oxaliplatin and topotecan infusion in patients with previously treated ovarian cancer. [Abstract]. Proc. Am. Soc. Clin. Oncol. 22 (2003) [Abstract 1860]